{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T12:25:48Z","timestamp":1750508748029,"version":"3.41.0"},"reference-count":30,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Psoriasis is a chronic skin disease for which there is no cure. However, the systemic treatment of psoriasis has undergone a revolution over the last few decades and now offers many different options. With more effective treatments available, the endpoints for successful treatment have also changed. The choice of systemic treatment depends on various factors as summarised in this review.<\/jats:p>","DOI":"10.61409\/v06240412","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T13:24:17Z","timestamp":1731331457000},"page":"1-7","source":"Crossref","is-referenced-by-count":1,"title":["Systemic treatments for psoriasis"],"prefix":"10.61409","author":[{"given":"Anne Hald","family":"Rittig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trine","family":"Bertelsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"R\u00f8nholt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Torres T, Puig L. Treatment goals for psoriasis: should PASI 90 become the standard of care? Actas Dermosifiliogr. 2015;106(3):155-157. https:\/\/doi.org\/10.1016\/j.ad.2014.10.001","DOI":"10.1016\/j.ad.2014.10.001"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Jolliffe DM. A history of the use of arsenicals in man. J R Soc Med. 1993;86(5):287-289. https:\/\/doi.org\/10.1177\/014107689308600515","DOI":"10.1177\/014107689308600515"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Cuzick J, Sasieni P, Evans S. Ingested arsenic, keratoses, and bladder cancer. Am J Epidemiol. 1992;136(4):417-421. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a116514","DOI":"10.1093\/oxfordjournals.aje.a116514"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Lynn S, Lai HT, Gurr JR, Jan KY. Arsenite retards DNA break rejoining by inhibiting DNA ligation. Mutagenesis. 1997;12(5):353-358. https:\/\/doi.org\/10.1093\/mutage\/12.5.353","DOI":"10.1093\/mutage\/12.5.353"},{"key":"ref4","unstructured":"Dunn LK, Gaar LR, Yentzer BA et al. Acitretin in dermatology: a review. J Drugs Dermatol. 2011;10(7):772-782."},{"key":"ref5","unstructured":"Soleymani T, Vassantachart JM, Wu JJ. Comparison of guidelines for the use of cyclosporine for psoriasis: a critical appraisal and comprehensive review. J Drugs Dermatol. 2016;15(3):293-301."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"R\u00f8nholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297. https:\/\/doi.org\/10.3390\/ijms18112297","DOI":"10.3390\/ijms18112297"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Alabas OA, Mason KJ, Yiu ZZN et al. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR. Br J Dermatol. 2023;188(5):618-627. https:\/\/doi.org\/10.1093\/bjd\/ljad004","DOI":"10.1093\/bjd\/ljad004"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558-566. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08315.x","DOI":"10.1111\/j.1365-2133.2007.08315.x"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Warren RB, Mrowietz U, von Kiedrowski R et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10068):528-537. https:\/\/doi.org\/10.1016\/S0140-6736(16)32127-4","DOI":"10.1016\/S0140-6736(16)32127-4"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Lee CS, Li K. A review of acitretin for the treatment of psoriasis. Expert Opin Drug Saf. 2009;8(6):769-779. https:\/\/doi.org\/10.1517\/14740330903393732","DOI":"10.1517\/14740330903393732"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Colombo MD, Cassano N, Bellia G, Vena GA. Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. ScientificWorldJournal. 2013;2013:805705. https:\/\/doi.org\/10.1155\/2013\/805705","DOI":"10.1155\/2013\/805705"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Paziana K, Del Monaco M, Cardonick E et al. Ciclosporin use during pregnancy. Drug Saf. 2013;36(5):279-294. https:\/\/doi.org\/10.1007\/s40264-013-0034-x","DOI":"10.1007\/s40264-013-0034-x"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Chambers CD, Johnson DL, Xu R et al. Birth outcomes in women who have taken adalimumab in pregnancy: a prospective cohort study. PLoS One. 2019;14(10):e0223603. https:\/\/doi.org\/10.1371\/journal.pone.0223603","DOI":"10.1371\/journal.pone.0223603"},{"key":"ref14","unstructured":"https:\/\/dds.nu\/wp-content\/uploads\/2024\/03\/Guideline-DDS-2.-generations-immunomodulatorisk-behandling-opdatering-december-2023_Final-1.pdf. (28. sep 2024)."},{"key":"ref15","unstructured":"https:\/\/www.guidelines.edf.one\/\/uploads\/attachments\/clv20jpg13acsxcjrux8329gn-0-euroguiderm-pso-gl-mar-2024.pdf. (28. sep 2024)."},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Loft ND, Vaengebjerg S, Halling AS et al. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol. 2020;34(6):1151-1160. https:\/\/doi.org\/10.1111\/jdv.16073","DOI":"10.1111\/jdv.16073"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Burmester GR, Gordon KB, Rosenbaum JT et al. Long-term safety of adalimumab in 29,967 adult patients from global clinical trials across multiple indications: an updated analysis. Adv Ther. 2020;37(1):364-380. https:\/\/doi.org\/10.1007\/s12325-019-01145-8","DOI":"10.1007\/s12325-019-01145-8"},{"key":"ref18","unstructured":"www.medicinraadet.dk (28. sep 2024)."},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Valenzuela F, Flores R. Immunogenicity to biological drugs in psoriasis and psoriatic arthritis. Clinics (Sao Paulo). 2021;76:e3015. https:\/\/doi.org\/10.6061\/clinics\/2021\/e3015","DOI":"10.6061\/clinics\/2021\/e3015"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Morita A, Strober B, Burden AD et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023;402(10412):1541-1551. https:\/\/doi.org\/10.1016\/S0140-6736(23)01378-8","DOI":"10.1016\/S0140-6736(23)01378-8"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Catlett IM, Hu Y, Gao L et al. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022;149(6):2010-2020.e8. https:\/\/doi.org\/10.1016\/j.jaci.2021.11.001","DOI":"10.1016\/j.jaci.2021.11.001"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Stein Gold LF, Bagel J, Tyring SK et al. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse). Br J Dermatol. 2023;189(5):540-552. https:\/\/doi.org\/10.1093\/bjd\/ljad252","DOI":"10.1093\/bjd\/ljad252"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Burlando M, Campione E, Cuccia A et al. Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus. Dermatol Reports. 2023;15(2):9613. https:\/\/doi.org\/10.4081\/dr.2023.9613","DOI":"10.4081\/dr.2023.9613"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Torres T, Chiricozzi A, Puig L et al. Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 inhibitors: a retrospective, multinational, multicentre study. Am J Clin Dermatol. 2024;25(2):333-342. https:\/\/doi.org\/10.1007\/s40257-024-00845-4","DOI":"10.1007\/s40257-024-00845-4"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Vangilbergen M, Stockman A, Van De Velde A et al. The role of IL-17 and IL-23 inhibitors in the development, progression, and recurrence of cancer: a systematic review. JAAD International (online 16. aug 2024). https:\/\/doi.org\/10.1016\/j.jdin.2024.06.006","DOI":"10.1016\/j.jdin.2024.06.006"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change. J Eur Acad Dermatol Venereol. 2021;35(4):824-834. https:\/\/doi.org\/10.1111\/jdv.16866","DOI":"10.1111\/jdv.16866"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Romero IB, Dauden E, Foraster CF et al. PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. J Dermatolog Treat. 2022;33(3):1661-1669. https:\/\/doi.org\/10.1080\/09546634.2021.1890683","DOI":"10.1080\/09546634.2021.1890683"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Svendsen MT, Feldmann S, Tiedemann SN et al. Improving psoriasis patients' adherence to topical drugs: a systematic review. J Dermatolog Treat. 2020;31(8):776-785. https:\/\/doi.org\/10.1080\/09546634.2019.1623371","DOI":"10.1080\/09546634.2019.1623371"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Antonatos C, Asmenoudi P, Panoutsopoulou M, Vasilopoulos Y. Pharmaco-omics in psoriasis: paving the way towards personalized medicine. Int J Mol Sci. 2023;24(8):7090. https:\/\/doi.org\/10.3390\/ijms24087090","DOI":"10.3390\/ijms24087090"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:27:07Z","timestamp":1747898827000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V06240412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":30,"URL":"https:\/\/doi.org\/10.61409\/v06240412","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2024,11,11]]}}}